Skip to main content
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1986 Jan 11;292(6513):79–80. doi: 10.1136/bmj.292.6513.79

Effective short term treatment of Paget's disease with oral etidronate.

C J Preston, A J Yates, M N Beneton, R G Russell, R E Gray, R Smith, J A Kanis
PMCID: PMC1339104  PMID: 3080099

Abstract

Twelve patients with Paget's disease of bone were treated with high doses of disodium etidronate for one month and compared with patients given treatments for longer periods. The effects of treatment for one month with etidronate 20 mg/kg daily were indistinguishable from six months' continuous treatment with the same dose but significantly better than treatment with 5 mg/kg daily in suppressing biochemical indices of disease activity. Treatment for one month was associated with transient osteomalacia but sustained suppression of bone resorption. Short term treatments with high doses of disodium etidronate may maximise suppression of disease activity but decrease exposure to unwanted effects.

Full text

PDF
79

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman R. D., Johnston C. C., Khairi M. R., Wellman H., Serafini A. N., Sankey R. R. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med. 1973 Dec 27;289(26):1379–1384. doi: 10.1056/NEJM197312272892601. [DOI] [PubMed] [Google Scholar]
  2. Boyce B. F., Smith L., Fogelman I., Johnston E., Ralston S., Boyle I. T. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet. 1984 Apr 14;1(8381):821–824. doi: 10.1016/s0140-6736(84)92272-4. [DOI] [PubMed] [Google Scholar]
  3. Kanis J. A. Monitoring the treatment of Paget's disease with etidronate. Calcif Tissue Int. 1984 Dec;36(6):629–631. doi: 10.1007/BF02405380. [DOI] [PubMed] [Google Scholar]
  4. Nagant de Deuxchaisnes C., Rombouts-Lindemans C., Huaux J. P., Devogelaer J. P. Diphosphonates and inhibition of bone mineralization. Lancet. 1982 Sep 11;2(8298):607–608. doi: 10.1016/s0140-6736(82)90681-x. [DOI] [PubMed] [Google Scholar]
  5. Russell R. G., Smith R., Preston C., Walton R. J., Woods C. G. Diphosphonates in Paget's disease. Lancet. 1974 May 11;1(7863):894–898. doi: 10.1016/s0140-6736(74)90347-x. [DOI] [PubMed] [Google Scholar]
  6. Walton R. J., Russell R. G., Smith R. Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man. Clin Sci Mol Med. 1975 Jul;49(1):45–56. doi: 10.1042/cs0490045. [DOI] [PubMed] [Google Scholar]
  7. Yates A. J., Percival R. C., Gray R. E., Atkins R. M., Urwin G. H., Hamdy N. A., Preston C. J., Beneton M. N., Russell R. G., Kanis J. A. Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet. 1985 Jun 29;1(8444):1474–1477. doi: 10.1016/s0140-6736(85)92253-6. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES